SR-141716A-induced stimulation of locomotor activity: A structure-activity relationship study

Pharmacology Biochemistry and Behavior

Volumn 74, Issue 1, 2002, Pages 31-40

  Bass, Caroline E ^a   Griffin, Graeme ^a   Grier, Mark ^b   Mahadevan, Anu ^b   Razdan, Raj K ^b   Martin, Billy R ^a,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Organix   (United States)

^c PO Box 980613 ^*  (United States)

Author keywords

Behavior; Cannabinoid receptor; Locomotor activity; SR 141716A; Stimulation

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); O 1247; O 1248; O 1253; O 1254; O 1255; O 1269; O 1270; O 1271; O 1272; O 1300; O 1302; O 1343; O 1412; O 1559; O 1654; O 1655; O 1690; O 1691; O 1710; O 1803; RIMONABANT; SULFUR 35; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; TASK PERFORMANCE;

ANIMALS; CYCLOHEXANOLS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); MALE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; STIMULATION, CHEMICAL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036887557     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(02)00945-0     Document Type: Article

References (14)

1. Adams I.B., Compton D.R., Martin B.R. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J. Pharmacol. Exp. Ther. 284:1998;1209-1217.
2. Breivogel C.S., Griffin G., Di Marzo V., Martin B.R. Evidence for a new G-protein coupled receptor in mouse brain. Mol. Pharmacol. 60(1):2001;155-163.
3. Compton D.R., Rice K.C., De Costa B.R., Razdan R.K., Melvin L.S., Johnson M.R., Martin B.R. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J. Pharmacol. Exp. Ther. 265:1993;218-226.
4. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 277:1996;586-594.
5. Glass M., Northup J.K. Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol. Pharmacol. 56:1999;1362-1369.
6. Hajos N., Ledent C., Freund T.F. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience. 106:2001;1-4.
7. Katona I., Sperlagh B., Sik A., Kafalvi A., Vizi E.S., Mackie K., Freund T.F. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci. 19:1999;4544-4558.
8. Milligan G., Bond R.A., Lee M. Inverse agonism: pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol. Sci. 16:1995;10-13.
9. Richardson J.D., Aanonsen L., Hargreaves K.M. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur. J. Pharmacol. 319:1997;R3-R4.
10. Rinaldi-Carmona M., Barth F., Héaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Néliat G., Caput D., Ferrara P., Soubrié P., Brelière J.C., Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
11. Santucci V., Storme J.J., Soubrie P., Le Fur G. Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci. 58:1996;L103-L110.
12. 35S]thio]-triphosphate binding. Proc. Natl. Acad. Sci. U. S. A. 92:1995;7242-7246.
13. Sim-Selley L., Brunk L., Selley D. Inhibitory effects of SR-141716A on G-protein activation in rat brain. Eur. J. Pharmacol. 414:2001;135-143.
14. Terranova J.-P., Michaud J.-C., Le Fur G., Soubrie P. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and win55212-2: reversal by sr141716A, a selective antagonist of cb1 cannabinoid receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 352:1995;576-579.